(GTT); all may metastasize and are potentially fatal if untreated 1 . The incidence of hydatidiform mole varies in different regions of the world, but now has been falling 1 . Highest incidence of 12.1/1000 deliveries was reported from Turkey. The malignant potential of this disease is higher in South East Asia where it can be as high as 10-15% in comparison to 2-4% in the western countries 2 .
In persistent trophoblastic disease (PTD), trophoblastic activity remains after evacuation of hydatidiform mole as shown by subsequent high or even rising βhCG concentration in blood. The reported frequency of PTD is 20% in complete hydatidiform mole and 0.5 to 9.9% in partial hydatidiform mole. In order to prevent complication from metastatic disease, PTD needs to be treated early. Prophylactic chemotherapy (started immediately after evacuation of the mole) reduces the incidence of PTD to 4-12% 1 . Because of the large proportion of patients show spontaneous remission of molar pregnancy after evacuation and because of the side effects of chemotherapy, clinicians are reluctant to use prophylactic chemotherapy. It would therefore be helpful to identify the patients at risk for developing PTD 3 .
Various risk factors for post molar trophoblastic disease has been reported such as pre evacuation β hCG level, maternal age, gestational age, histologic grade of molar tissue, uterine size, ovarian cyst, presence of medical complication, previous molar pregnancy and ABO blood groups were evaluated 4 .
Gestational trophoblastic disease can occur after any type of antecedent pregnancy. The most frequent antecedent pregnancy is that of a patient presenting with a hydatidiform mole. Nearly 45% of choriocarcinomas follow evacuation of hydatidiform mole, 25% follow after full term normal pregnancy, 25% follow spontaneous abortion and 5% ectopic pregnancy 5 .
The leading symptom of persistent trophoblastic disease is irregular uterine haemorrhage coming sooner or later after the expulsion of a mole or a normal pregnancy. Often the disease presents by way of its metastasis. Thus the occurrence of a haemothorax, a complaint of dyspnoea or haemoptysis or the appearance of neurological signs and symptoms such as headache , visual disturbances or focal neurological deficits can be the first evidence of choriocarcinoma 6 .
Patients with gestational trophoblastic tumors are stratified into low and high risk groups which have different treatments and outcomes. A number of factors are used to stratify patients into high and low risk groups. Each factor scores numerical points. A score >6 (FIGO score) or >8 (Charring cross score) defines high risk disease 7 . Low risk patients are usually treated with single agent chemotherapy. Approximately 85-90% of patients in this group are cured by the initial chemotherapy regimen. Most of the others respond to alternate drugs; combination chemotherapy is rarely needed. High risk patients require combination chemotherapy with a selective use of surgery and radiotherapy 1 .
Since there are well known side effects of all the chemotherapeutic drugs, a careful check is made before a course of treatment is commenced or continued. The principal adverse effects are on the bone marrow, liver and kidney, so regular checks are made on white cell count, platelets, liver function and blood urea 6 .
Materials and Methods:
This prospective observational study was carried out in the department of Obstetrics & Gynaecology, Mymensingh Medical College Hospital, Bangladesh. from July, 2008 to June, 2009. Fifty patients of persistent trophoblastic disease, who were admitted during this period were selected as study population. In this study, there were 49 patients with histologically confirmed molar pregnancies; complete moles in 46 patients and partial moles in 3 patients. One patient had antecedent missed abortion which was not histologically confirmed.
Persistent disease was determined on the basis of the following criteria-(a) Two or more consecutive weekly increase in beta hCG level.
(b) Plateauing of the beta hCG level for three or more consecutive weeks.
(c) Persistent or recurrent uterine haemorrhage and a persistently detectable beta hCG titre. Patients with non metastatic trophoblastic disease and low risk metastatic trophoblastic disease were offered single agent chemotherapy with methotrexate and folinic acid rescue in consultation with the oncologist. When β hCG response was inadequate, multi-agent chemotherapy was given. Complications of chemotherapy were also observed and supportive treatment was given.
Sampling Method was Purposive non randomized method. A structured questionnaire was developed addressing all the variables of interest which was finalized following pre-testing.
Data was processed using software SPSS (Statistical Package for Social Science).
Results:
A total of 50 subjects of persistant trophoblastic disease were included in the present study. Subjects were categorized into different groups, their frequencies with percentages were calculated, significance levels and mean ± SD were determined by chi square test and one sample "t" test with the help of computer windows SPSS.
Figure-I: Antecedent Pregnancy (n=50): 49(98%) of them were due to post molar trophoblastic disease and 01(02%) due to missed abortion (Fig I) . Among the post -molar trophoblastic disease 46 (92%) due to complete mole and 3 (06%) due to partial mole. Complete mole was statistically significant (p=0.001). Features of distant metastasis of the study subjects (n=50): 47(94%) of the study subjects have no features of distant metastasis but 02(04%) had pulmonary metastasis and one (02%) case had metastatic nodules in vagina. Non metastatic cases were significantly higher. Table-2 Uterine size of the study subjects (n= 50): Uterine size were normal in 17(34%), 6-8 wks in 30(61%), 9-12 wks size in 2(4%) and >12 wks were in 1(2%) case. Uterine size 6-8 wks group were significantly higher.
Figure-6: Treatment given to the study subjects (n=50): 43(86%) of the study subjects were treated with chemotherapy alone and 07(14%) had both hysterectomy and chemotherapy. Figure-7: Type of chemotherapy given to the study subjects (n=50): Single agent chemotherapy were received by 47(94%) and multiple agent (Etoposide, Methotrexate, Actinomycin D and Cyclophosphamide) by 03(06%) of the study subjects. Figure-8 : The outcome of the study subjects (n=50): After chemotherapy, 11(22%) patients were cured, 38(76%) had declining â hCG level, and 1(2%) had static β hCG level. Declining β HCG level was significantly higher. Figure-10: The effect of chemotherapy on β hCG of the study subjects (n=50): Mean ± SD of post evacuation β hCG was 84551 ± 39901, mean ± SD of β hCG levels after 1 st dose of chemotherapy was 19854±14808 and mean ± SD of β hCG levels after 4 th dose of chemotherapy was 84 ± 50 (Fig X) . The differences were statistically significant. were not found to be strongly associated with risk of persistent disease 7, 8 . In another study in India, 47.47 % patients were in between 20 and 25, 28% were less than 20 years of age and 24% were in > 25 years 9 . In Philippines, one study reported 44% of cases in between 25-34 years and least number of cases in extremes of age 10 .
Discussion
In this study, 28 (57.14%) patients had associated theca lutein cyst. But it was statistically in significant. But Tchan Kyu Park found the presence of theca lutein cyst as a significant risk factor 4 .
Antecedent pregnancy
In this study, among 50 patients of PTD, the antecedent pregnancy was molar in 49 (98%) and missed abortion in one (2%) case. Among PTD, 46 (92%) were due to complete mole and 3 (6%) due to partial mole.
In Pakistan one study reported among the persistent trophoblastic disease, in 40% cases antecedent pregnancy was hydatidiform mole, and while 60% cases it was spontaneous abortion 11 . In Charing Cross Hospital 602 patients treated between 1985 to 1994, there were 100 cases (16.6%) where the antecedent pregnancy was either a non-molar abortion or a live birth, rest of the cases were molar pregnancy 12 .
Clinical Presentation
In the present study, 40(80%) patients presented with irregular pervaginal bleeding which was statistically significant. (p<0.001), 4 (08%) presented with amenorrhoea and 3(06%) presented with metastasis, 32 (64%) presented with uterine size more than normal, 28(56%) with tubo-ovarian mass.
In one study in India 20 cases with GTD were presented with abnormal vaginal bleeding 13 .
In a study in Charring cross hospital, among 602 patients between 1985-1994, approximately two-third (66.67%) presented with varying degrees of vaginal bleeding but in one-quarter (25%) of these patients the primary complaint was associated with symptoms from metastatic disease involving lung, brain or abdomen 12 .
Outcome of chemotherapy in persistent trophoblastic disease
In the present study 43 (86%) patients were treated with chemotherapy and 7(14%) patients were treated with hysterectomy followed by chemotherapy. All patients started with single agent methotrexate but subsequently 94% patients responded to single agent and 6% needed salvage therapy with multiple agent chemotherapy (EMA-CO). After 4 cycles of chemotherapy 22% patients cured completely, 76% had declining β hCG level and 2% had static β hCG level. Overall remission was 98%. Mean ± SD of â hCG levels after 1 st dose of chemotherapy was 19854±14808 and after 4 th dose of chemotherapy was 84 ± 50 (Table IX and Fig X) . The differences were statistically significant.
In India one study showed almost 90% patient cured with methotrexate (MTX), 2.2% cases were treated with multiple agent chemotherapy. Case fatality was 2.02% 11 . Another study showed 92.9% remission rate of low risk GTN with MTX. Rest of the cases required multiagent chemotherapy 14 .
In Manila, one study reported sustained remission rate 98.5% with chemotherapy for non metastatic GTN and LRM GTN (Low risk metastatic GTN) 12 while Wong reported 91.5% cure rate with MTX 15 .
In United Kingdom, one study showed 94.4% cure rate of LRMGTN with MTX while 5.55% required salvage chemotherapy 16 .
Chemotherapy complication: The toxicity of chemotherapy has been reported to occur in 16.9% to 70.2% of the cases. Some deaths due to drug toxicity has been reported. In Korea one study showed chemotherapy was well tolerated without serious toxicities 13 . Hepatotoxicity was observed frequently with MTX, CVF regimen. Gastro intestinal symptoms mainly nausea, vomiting occurred frequently when actinomycin D was given. Haematological toxicity was transient and mild. Alopecia was minimal and reversible. Stomatitis was also mild and transitory. 4 In the present study, complications of chemotherapy were found only in 10% of patients. Among them 4%had liver dysfunction, 4%had stomatitis and 2% had both gastrointestinal symptoms and stomatitis.
In Pakistan one study showed after administration of EMA-CO therapy, 100% patient developed nausea, vomiting, anorexia; 60% patient developed alopecia and 20% patient developed bone marrow depression. 11 In United Kingdom one study showed 25% patient developed serosal symptoms with low dose MTX and folinic acid regimen, among them pleurisy was the commonest complaint. 17 On the other hand Wong reported no significant side effects except Steven Johnson Syndrome in one case 15 .
Conclusion:
Most common presenting complaint of PTD was irregular per vaginal bleeding. Serial β hCG levels remain the best monitor for following up a molar pregnancy and for determining response to treatment.
Methotrexate infusion therapy described in this study is effective in the treatment of non metastatic GTD and low risk metastatic GTD. Neither severe complication nor death occurred due to toxicity.
